Clinical usage recommendations and analytic performance goals for total and free triiodothyronine measurements.
The major clinical role for total triiodothyronine (TT3) and (or) free T3 (FT3) is the assessment of hyperthyroidism in patients with suppressed sensitive thyrotropin (sTSH) concentrations. The assays are particularly important in hyperthyroid patients with normal free thyroxine (FT4) concentrations to assess potential T3 thyrotoxicosis. Other specialized uses for T3 and FT3 measurements are monitoring thyroid hormone replacement therapy, the evaluation of amiodarone-induced thyrotoxicosis, and predicting outcome of antithyroid drug therapy in patients with Graves hyperthyroidism. The roles of these tests in assessing heart function in cardiopulmonary bypass surgery, evaluation of patients with neuropsychiatric disorders, and monitoring of patients on anticonvulsant therapy are not well defined. These assays are not recommended for diagnosis of hypothyroidism. Analytic recommendations include CV < 5.2% for T3 and < 3.8% for FT3; < 0.2% cross-reactivity with L-T4; and < 1.0% cross-reactivity with D-T4, D-T3, and reverse T3.
Klee
G G
GG
Mayo Clinic and Foundation, Rochester, MN 55905, USA. klee.george@mayo.edu
D006111:Graves Disease / Q000097:blood / Q000188:drug therapy; D017408:Guidelines as Topic; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood; D007037:Hypothyroidism / Q000097:blood; D013963:Thyroid Hormones / Q000008:administration & dosage; D016896:Treatment Outcome; D014284:Triiodothyronine / Q000097:blood*
D013963:Thyroid Hormones; D014284:Triiodothyronine